永福股份(300712.SZ):聯合體中標2062萬元的熱電儲能工程項目
格隆匯6月8日丨永福股份(300712.SZ)公佈,公司於近日收到國網時代華電大同熱電儲能工程(全過程工程諮詢服務項目)的《中標通知書》,公司與山東誠信工程建設監理有限公司)“山東誠信監理”)組成的聯合體為該項目中標人,中標金額人民幣2062萬元(具體金額以屆時簽訂的正式合同為準)。
項目規模:新建磷酸鐵鋰電池儲能系統一套,建設規模為150MW/300MWh,預計佔地25000平方米。
該項目中標金額2062萬元,根據投標階段聯合體雙方約定的合同工作量劃分,公司所佔金額約1649.6萬元,約佔公司2020年度經審計勘測設計業務營業收入27980.3415萬元的5.90%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.